Mohamed I. Husseiny

Prof. Mohamed I. Husseiny

Translational Research & Cellular Therapeutics, Beckman Research Institute of City of Hope, Duarte, California, USA
orcid
Associate Research Professor

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2007 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
Mohamed I. HusseinyMohamed I. Husseiny
Mohamed I. Husseiny
MEM. Abd El-Aziz
M. Abd El-Aziz
YBY. Badr
Y. Badr
MMM.A. Mahmoud
M.A. Mahmoud

4 September 2007 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Ashraf IbrahimAshraf Ibrahim
Ashraf Ibrahim
TGTeclegiorgis Gebermariam
Teclegiorgis Gebermariam
YFYue Fu
Yue Fu
LLLin Lin
Lin Lin
Mohamed I. HusseinyMohamed I. Husseiny
Mohamed I. Husseiny
BSBrad J. Spellberg
Brad J. Spellberg
Mucormycosis causes mortality in at least 50% of cases despite current first-line therapies. Clinical and animal data indicate that the presence of elevated available serum iron predisposes the host to mucormycosis. Here we demonstrate that deferasirox, an iron chelator recently approved for use in humans by the US FDA, is a highly effective treatment for mucormycosis. Deferasirox effectively chelated iron from Rhizopus oryzae and demonstrated cidal activity in vitro against 28 of 29 clinical isolates of Mucorales at concentrations well below clinically achievable serum levels. When administered to diabetic ketoacidotic or neutropenic mice with mucormycosis, deferasirox significantly improved survival and decreased tissue fungal burden, with an efficacy similar to that of liposomal amphotericin B. Deferasirox treatment also enhanced the host inflammatory response to mucormycosis. Most importantly, deferasirox synergistically improved survival and reduced tissue fungal burden when combined with liposomal amphotericin B. These data support clinical investigation of adjunctive deferasirox therapy to improve the poor outcomes of mucormycosis with current therapy. As iron availability is integral to the pathogenesis of other infections (e.g., tuberculosis, malaria), broader investigation of deferasirox as an antiinfective treatment is warranted.

18 July 2010 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
Ashraf IbrahimAshraf Ibrahim
Ashraf Ibrahim
TGTeclegiorgis Gebremariam
Teclegiorgis Gebremariam
LLLin Lin
Lin Lin
GLGuanpingsheng Luo
Guanpingsheng Luo
Mohamed I. HusseinyMohamed I. Husseiny
Mohamed I. Husseiny
BSBrad Spellberg
Brad Spellberg
Summary: Rhizopus oryzaeis the most common cause of mucormycosis, an angioinvasive fungal infection that causes more then 50% mortality rate despite first‐line therapy. Clinical and animal model data clearly demonstrate that the presence of elevated available serum iron predisposes the host to mucormycosis. The high affinity iron permease gene (FTR1) is required forR. oryzaeiron transport in iron‐depleted environments. Here we demonstrate thatFTR1is required for full virulence ofR. oryzaein mice. We show thatFTR1is expressed during infection in diabetic ketoacidosis (DKA) mice. In addition, we disruptedFTR1by double cross‐over homologous recombination, but multinucleatedR. oryzaecould not be forced to segregate to a homokaryotic null allele. Nevertheless, a reduction of the relative copy number ofFTR1and inhibition ofFTR1expression by RNAi compromised the ability ofR. oryzaeto acquire ironin vitroand reduced its virulence in DKA mice. Importantly, passive immunization with anti‐Ftr1p immune sera protected DKA mice from infection withR. oryzae. Thus,FTR1is a virulence factor forR. oryzae, and anti‐Ftr1p passive immunotherapy deserves further evaluation as a strategy to improve outcomes of deadly mucormycosis.

1 December 2006 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
KMKamel Metwally
Kamel Metwally
LALobna M. Abdel-Aziz
Lobna M. Abdel-Aziz
ELEl-Sayed M. Lashine
El-Sayed M. Lashine
Mohamed I. HusseinyMohamed I. Husseiny
Mohamed I. Husseiny
RBRania H. Badawy
Rania H. Badawy

23 March 2010 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
GXGuosheng Xiong
Guosheng Xiong
Mohamed I. HusseinyMohamed I. Husseiny
Mohamed I. Husseiny
LSLiping Song
Liping Song
AEAnat Erdreich‐Epstein
Anat Erdreich‐Epstein
GSGregory M. Shackleford
Gregory M. Shackleford
LMLeonid S. Metelitsa
Leonid S. Metelitsa
Although tumors express potentially immunogenic tumor‐associated antigens (TAAs), cancer vaccines often fail because of inadequate antigen delivery and/or insufficient activation of innate immunity. Engineering nonpathogenic bacterial vectors to deliver TAAs of choice may provide an efficient way of presenting TAAs in an immunogenic form. In this study, we used genes of Salmonella pathogenicity island 2 (SPI2) to construct a novel cancer vaccine in which a TAA, survivin, was fused to SseF effector protein and placed under control of SsrB, the central regulator of SPI2 gene expression. This construct uses the type III secretion system (T3SS) of Salmonella and allows preferential delivery of tumor antigen into the cytosol of antigen‐presenting cells for optimal immunogenicity. In a screen of a panel of attenuated strains of Salmonella, we found that a double attenuated strain of Salmonella typhimurium, MvP728 (purD/htrA), was not toxic to mice and effectively expressed and translocated survivin protein inside the cytosol of murine macrophages. We also found that a ligand for CD1d‐reactive natural killer T (NKT) cells, α‐glucuronosylceramide (GSL1), enhanced MvP728‐induced interleukin‐12 production in human dendritic cells and that in vivo coadministration of a NKT ligand with MvP728‐Llo or MvP728‐survivin enhanced effector‐memory cytotoxic T lymphocyte (CTL) responses. Furthermore, combined use of MvP728‐survivin with GSL1 produced antitumor activity in mouse models of CT26 colon carcinoma and orthotopic DBT glioblastoma. Therefore, the use of TAA delivery via SPI‐2‐regulated T3SS of Salmonella and NKT ligands as adjuvants may provide a foundation for new cancer vaccines.

10 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Mohamed I. HusseinyMohamed I. Husseiny
Mohamed I. Husseiny
AKAlexander Kaye
Alexander Kaye
EZEmily Zebadua
Emily Zebadua
FKFouad Kandeel
Fouad Kandeel
KFKevin Ferreri
Kevin Ferreri
The onset of metabolic dysregulation in type 1 diabetes (T1D) occurs after autoimmune destruction of the majority of pancreatic insulin-producing beta cells. We previously demonstrated that the DNA encoding the insulin gene is uniquely unmethylated in these cells and then developed a methylation-specific PCR (MSP) assay to identify circulating beta cell DNA in streptozotocin-treated mice prior to the rise in blood glucose. The current study extends to autoimmune non-obese diabetic (NOD) mice and humans, showing in NOD mice that beta cell death occurs six weeks before the rise in blood sugar and coincides with the onset of islet infiltration by immune cells, demonstrating the utility of MSP for monitoring T1D. We previously reported unique patterns of methylation of the human insulin gene, and now extend this to other human tissues. The methylation patterns of the human insulin promoter, intron 1, exon 2, and intron 2 were determined in several normal human tissues. Similar to our previous report, the human insulin promoter was unmethylated in beta cells, but methylated in all other tissues tested. In contrast, intron 1, exon 2 and intron 2 did not exhibit any tissue-specific DNA methylation pattern. Subsequently, a human MSP assay was developed based on the methylation pattern of the insulin promoter and human islet DNA was successfully detected in circulation of T1D patients after islet transplantation therapy. Signal levels of normal controls and pre-transplant samples were shown to be similar, but increased dramatically after islet transplantation. In plasma the signal declines with time but in whole blood remains elevated for at least two weeks, indicating that association of beta cell DNA with blood cells prolongs the signal. This assay provides an effective method to monitor beta cell destruction in early T1D and in islet transplantation therapy.